Putting Patients First

Priority: Advocate for more effective and less toxic breast cancer treatments by shifting the balance of power in the Food and Drug Administration’s drug approval process away from the pharmaceutical industry and towards the public interest. Our independence from pharmaceutical company funding puts us in a unique position in the breast cancer movement to advance this ambitious goal. And the need for this work becomes more evident everyday. Whether the problem is the FDA approving drugs for breast cancer treatment like Avastin before they have been shown to improve either survival or quality of life for breast cancer patients, or the need to pay attention to emerging dangerous side effects of drugs like ESA’s that have been heavily marketed to breast patients, BCA will always put the needs of women with breast cancer first, and motivate the FDA to do the same.

Learn more about BCA's Advocacy at the FDA

Read BCA's policies on breast cancer issues